• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

硼替佐米与肿瘤坏死因子相关凋亡诱导配体协同相互作用的新见解：tBid起连接作用。

Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link.

作者信息

Fulda Simone

机构信息

Institute for Experimental Cancer Research in Pediatrics, Goethe-University Frankfurt, Komturstr. 3a, 60528 Frankfurt, Germany. Simone Fulda.

出版信息

Oncotarget. 2011 May;2(5):418-21. doi: 10.18632/oncotarget.277.

DOI:10.18632/oncotarget.277
PMID:21789791
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3248183/
Abstract

The proteasome inhibitor Bortezomib has been identified as a potent enhancer of TRAIL-induced apoptosis in several human cancers. However, the identification of the underlying molecular mechanisms of this synergistic cell death induction has been ongoing over the last years. A recent study identifies a new mechanism of action for the synergism of TRAIL and Bortezomib.

摘要

蛋白酶体抑制剂硼替佐米已被确定为几种人类癌症中TRAIL诱导凋亡的有效增强剂。然而，过去几年一直在研究这种协同诱导细胞死亡的潜在分子机制。最近的一项研究确定了TRAIL与硼替佐米协同作用的一种新作用机制。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28b5/3248183/4b90bb048b46/oncotarget-02-418-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28b5/3248183/4b90bb048b46/oncotarget-02-418-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/28b5/3248183/4b90bb048b46/oncotarget-02-418-g001.jpg

相似文献

1
Novel insights into the synergistic interaction of Bortezomib and TRAIL: tBid provides the link.硼替佐米与肿瘤坏死因子相关凋亡诱导配体协同相互作用的新见解：tBid起连接作用。
Oncotarget. 2011 May;2(5):418-21. doi: 10.18632/oncotarget.277.
2
Bortezomib sensitises TRAIL-resistant HPV-positive head and neck cancer cells to TRAIL through a caspase-dependent, E6-independent mechanism.硼替佐米通过一种不依赖E6的半胱天冬酶依赖性机制，使对肿瘤坏死因子相关凋亡诱导配体（TRAIL）耐药的人乳头瘤病毒（HPV）阳性头颈部癌细胞对TRAIL敏感。
Cell Death Dis. 2014 Oct 23;5(10):e1489. doi: 10.1038/cddis.2014.455.
3
Bortezomib primes glioblastoma, including glioblastoma stem cells, for TRAIL by increasing tBid stability and mitochondrial apoptosis.硼替佐米通过增加 tBid 稳定性和线粒体凋亡使胶质母细胞瘤（包括胶质母细胞瘤干细胞）对 TRAIL 敏感。
Clin Cancer Res. 2011 Jun 15;17(12):4019-30. doi: 10.1158/1078-0432.CCR-11-0075. Epub 2011 Apr 27.
4
TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib.TRAIL疗法在非小细胞肺癌细胞中的作用：蛋白酶体抑制剂硼替佐米增强对死亡受体介导的细胞凋亡的敏感性
Mol Cancer Ther. 2007 Jul;6(7):2103-12. doi: 10.1158/1535-7163.MCT-07-0167.
5
Bortezomib restores stroma-mediated APO2L/TRAIL apoptosis resistance in multiple myeloma.硼替佐米恢复骨髓基质介导的 APO2L/TRAIL 凋亡抵抗在多发性骨髓瘤中。
Eur J Haematol. 2010 Mar;84(3):212-22. doi: 10.1111/j.1600-0609.2009.01381.x. Epub 2009 Nov 17.
6
Bortezomib blocks Bax degradation in malignant B cells during treatment with TRAIL.硼替佐米在TRAIL治疗期间可阻断恶性B细胞中Bax的降解。
Blood. 2008 Mar 1;111(5):2797-805. doi: 10.1182/blood-2007-08-110445. Epub 2007 Dec 26.
7
Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL.蛋白酶体抑制剂硼替佐米可诱导尤因肉瘤家族性肿瘤来源的细胞系发生细胞周期阻滞和凋亡，并与肿瘤坏死因子相关凋亡诱导配体（TRAIL）协同作用。
Cancer Biol Ther. 2008 Apr;7(4):603-8. doi: 10.4161/cbt.7.4.5564. Epub 2008 Jan 11.
8
Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways.硼替佐米通过激活外源性和内源性凋亡途径，使人类食管鳞癌细胞对 TRAIL 介导的凋亡敏感。
Mol Cancer Ther. 2010 Jun;9(6):1842-51. doi: 10.1158/1535-7163.MCT-09-0918. Epub 2010 Jun 1.
9
Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation.蛋白酶体抑制剂介导的TRAIL再敏化和Bik积累。
Cancer Biol Ther. 2005 Jul;4(7):781-6. doi: 10.4161/cbt.4.7.1897. Epub 2005 Jul 6.
10
A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma.线粒体功能障碍和XIAP的表达导致结肠癌转移过程中对TRAIL诱导的细胞凋亡产生抗性。
Oncogene. 2008 Oct 9;27(46):6012-22. doi: 10.1038/onc.2008.197. Epub 2008 Jun 16.

引用本文的文献

1
Generation of TRAIL-resistant cell line models reveals distinct adaptive mechanisms for acquired resistance and re-sensitization.生成 TRAIL 耐药细胞系模型揭示了获得性耐药和再敏化的不同适应机制。
Oncogene. 2021 May;40(18):3201-3216. doi: 10.1038/s41388-021-01697-6. Epub 2021 Mar 25.
2
PPARγ activation by troglitazone enhances human lung cancer cells to TRAIL-induced apoptosis via autophagy flux.曲格列酮激活过氧化物酶体增殖物激活受体γ通过自噬通量增强人肺癌细胞对肿瘤坏死因子相关凋亡诱导配体诱导的凋亡作用。
Oncotarget. 2017 Apr 18;8(16):26819-26831. doi: 10.18632/oncotarget.15819.
3
Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma.

本文引用的文献

1
Bortezomib primes neuroblastoma cells for TRAIL-induced apoptosis by linking the death receptor to the mitochondrial pathway.硼替佐米通过将死亡受体与线粒体途径连接，使神经母细胞瘤细胞对 TRAIL 诱导的细胞凋亡敏感。
Clin Cancer Res. 2011 May 15;17(10):3204-18. doi: 10.1158/1078-0432.CCR-10-2451. Epub 2011 Apr 1.
2
Proteotoxic stress targeted therapy (PSTT): induction of protein misfolding enhances the antitumor effect of the proteasome inhibitor bortezomib.蛋白质毒性应激靶向治疗（PSTT）：诱导蛋白质错误折叠可增强蛋白酶体抑制剂硼替佐米的抗肿瘤作用。
Oncotarget. 2011 Mar;2(3):209-21. doi: 10.18632/oncotarget.246.
3
Hallmarks of cancer: the next generation.
染色体区域8p21缺失赋予多发性骨髓瘤患者对硼替佐米的抗性并与诱饵TRAIL受体表达上调相关。
PLoS One. 2015 Sep 17;10(9):e0138248. doi: 10.1371/journal.pone.0138248. eCollection 2015.
4
Carfilzomib enhances natural killer cell-mediated lysis of myeloma linked with decreasing expression of HLA class I.卡非佐米增强自然杀伤细胞介导的骨髓瘤细胞裂解，这与人类白细胞抗原I类分子表达降低有关。
Oncotarget. 2015 Sep 29;6(29):26982-94. doi: 10.18632/oncotarget.4831.
5
FTY720 enhances TRAIL-mediated apoptosis by up-regulating DR5 and down-regulating Mcl-1 in cancer cells.FTY720通过上调癌细胞中的DR5和下调Mcl-1来增强TRAIL介导的细胞凋亡。
Oncotarget. 2015 May 10;6(13):11614-26. doi: 10.18632/oncotarget.3426.
6
Selenocysteine derivative overcomes TRAIL resistance in melanoma cells: evidence for ROS-dependent synergism and signaling crosstalk.硒代半胱氨酸衍生物克服黑色素瘤细胞中的TRAIL耐药性：ROS依赖性协同作用和信号串扰的证据
Oncotarget. 2014 Sep 15;5(17):7431-45. doi: 10.18632/oncotarget.2008.
7
Accumulation of autophagosomes in breast cancer cells induces TRAIL resistance through downregulation of surface expression of death receptors 4 and 5.乳腺癌细胞中自噬体的积累通过下调死亡受体4和5的表面表达诱导肿瘤坏死因子相关凋亡诱导配体（TRAIL）抗性。
Oncotarget. 2013 Sep;4(9):1349-64. doi: 10.18632/oncotarget.1174.
8
Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling.将TRAIL与PI3激酶或HSP90抑制剂联合使用可通过抑制生存信号增强结肠癌细胞的凋亡。
Oncotarget. 2013 Aug;4(8):1185-98. doi: 10.18632/oncotarget.1162.
9
Combination of a selective activator of the glucocorticoid receptor Compound A with a proteasome inhibitor as a novel strategy for chemotherapy of hematologic malignancies.选择性糖皮质激素受体激活剂化合物 A 与蛋白酶体抑制剂联合用于血液系统恶性肿瘤的化疗新策略。
Cell Cycle. 2013 Jan 1;12(1):133-44. doi: 10.4161/cc.23048. Epub 2012 Dec 19.
10
Mislocalization of death receptors correlates with cellular resistance to their cognate ligands in human breast cancer cells.死亡受体的错误定位与人类乳腺癌细胞对其同源配体的细胞抗性相关。
Oncotarget. 2012 Aug;3(8):833-42. doi: 10.18632/oncotarget.542.
癌症的特征：下一代。
Cell. 2011 Mar 4;144(5):646-74. doi: 10.1016/j.cell.2011.02.013.
4
Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors.硼替佐米：在胃肠道间质瘤中一石二鸟
Oncotarget. 2010 May;1(1):6-8. doi: 10.18632/oncotarget.103.
5
Effects of bortezomib on human neuroblastoma cells in vitro and in a metastatic xenograft model.硼替佐米对人神经母细胞瘤细胞的体外及转移异种移植模型的作用。
Anticancer Res. 2009 Apr;29(4):1219-25.
6
Tumor resistance to apoptosis.肿瘤对细胞凋亡的抗性。
Int J Cancer. 2009 Feb 1;124(3):511-5. doi: 10.1002/ijc.24064.
7
Bortezomib as a therapeutic candidate for neuroblastoma.硼替佐米作为神经母细胞瘤的一种治疗候选药物。
J Exp Ther Oncol. 2008;7(2):135-45.
8
Effect of bortezomib on human neuroblastoma: analysis of molecular mechanisms involved in cytotoxicity.硼替佐米对人神经母细胞瘤的作用：对细胞毒性相关分子机制的分析
Mol Cancer. 2008 Jun 5;7:50. doi: 10.1186/1476-4598-7-50.
9
Targeting the extrinsic apoptosis pathway in cancer.靶向癌症中的外源性凋亡途径。
Cytokine Growth Factor Rev. 2008 Jun-Aug;19(3-4):325-31. doi: 10.1016/j.cytogfr.2008.04.001. Epub 2008 May 20.
10
Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region.蛋白酶体抑制剂PS-341（万珂）通过3'-非翻译区诱导肿瘤坏死因子相关凋亡诱导配体（TRAIL）受体DR5 mRNA的稳定。
Mol Cancer Ther. 2008 May;7(5):1091-100. doi: 10.1158/1535-7163.MCT-07-2368.